Wolverine Trading
TBPH icon

Wolverine Trading’s Theravance Biopharma TBPH Stock Holding History

Wolverine Trading’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12,409
Closed -$203K – 4982
2019
Q2 		$203K Buy
+12,409
New +$251K ﹤0.01% 3708

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wolverine Trading's TBPH Position: Q3 2019 in Review

Wolverine Trading sold out of Theravance Biopharma (TBPH) in Q3 2019, closing a stake of 12,409 shares — an estimated $203K sold.

Wolverine Trading first reported a position in TBPH in Q2 2019 and held it in 1 quarter. The position peaked at $203K in Q2 2019. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

  • Wolverine Trading reported no remaining Theravance Biopharma position as of Q3 2019 after selling out during the quarter.
  • Wolverine Trading sold 12,409 Theravance Biopharma shares in Q3 2019, an estimated $203K.
  • Wolverine Trading first reported a position in Theravance Biopharma in Q2 2019 and held it in 1 quarter.
  • Wolverine Trading's Theravance Biopharma position peaked at $203K in Q2 2019.
  • 92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Wolverine Trading's 13F filing for Q3 2019, filed 14 Nov 2019.